Introduction
Therapeutic approaches interfering with tumor angiogenesis have become fully incorporated into clinical practice nowadays (1) . In addition to anti-angiogenesis, a second, conceptually different strategy, "vascular targeting", takes advantage of tumor vessels for therapeutic purposes and aims at the selective pharmacodelivery of therapeutic payloads (e.g., drugs, cytokines, radionuclides) to the tumor site by their conjugation to carrier antibodies, which specifically home to tumor-associated vasculature (2) (3) (4) (5) . The approach benefits from the intrinsic accessibility of vascular targets and bypasses many of the hurdles associated with the targeting of cancer cell markers, such as physical and kinetic barriers of bulky tumors or antigen heterogeneity among tumor cells. Furthermore, whereas cancer cell surface proteins are in many cases shared by normal cells, vascular and stromal targets are available, which allow a clear-cut discrimination between healthy and neoplastic tissues (2, 3) . While it was initially assumed that vascular-targeting antibodies would mainly be relevant for solid tumors, we recently discovered that well-characterized vascular targets are abundantly expressed in hematologic malignancies such as Hodgkin and non-Hodgkin lymphomas, allowing the antibody-mediated deposition of bioactive payloads at the lymphoma site (6, 7) .
In 2000, we reported that acute myeloid leukemia (AML) is associated with extensive neovessel formation in the bone marrow (BM) (8) . In an attempt to evaluate a vascular-targeting strategy in AML, we have recently shown that the alternatively spliced extra-domains A (EDA-Fn) and B (EDB-Fn) of fibronectin and the extra-domain A1 of tenascin-C (TnC-A1) are abundantly expressed in AML BM and extramedullary AML lesions (5) . These markers are almost exclusively found in the tumor-associated vasculature and stroma while being virtually absent in normal organs and have been shown to be suited for site-specific pharmacodelivery approaches (2, 3, 9, 10) . In immunocompromised and immunocompetent mouse models of myelosarcoma-type AML, the antibody-mediated delivery of the pro-inflammatory cytokine interleukin-2 (IL2) to the leukemia-associated vasculature led to substantial leukemia growth retardation in a process mediated by CD8 + T cells and natural killer (NK) cells, while equivalent doses of non-targeted IL2 were ineffective (5) . Most importantly, the combination of the immunocytokine with cytarabine promoted complete leukemia eradications.
Here, we report the use of the immunocytokine F16-IL2, which mediates the selective delivery of human IL2 to TnC-A1, in combination with low-dose cytarabine In September 2013, NPM1-positive, FLT3-ITD-negative AML   relapse  was  diagnosed  with  the  karyotype 46,XY,t(2;3)(q?33;?),t(5;6)(q1?3;p15) [7] /46,XY [13] . At that time, the patient was reluctant to receive intensive chemotherapy followed by a second allo-HSCT. 
Methods

Patients and treatment
From June 2013 to December 2013, four AML patients who relapsed after multiple chemotherapies and one (n = 2) or two (n = 2) allo-HSCT were treated in a compassionate use setting with F16-IL2 and LDAC at the University Hospital Muenster, 
Histochemical analyses
For analysis of TnC-A1 expression, cryo-sections of pre-therapeutic BM biopsies were stained with biotinylated F16 as described (5) . Antibody detection was performed with streptavidin Alexa Fluor 488 (Invitrogen, Darmstadt, Germany). For analysis of in vivo targeting, F16-IL2 bound to its target in situ was detected in post-therapeutic BM specimens using the LSAB (labeled streptavidin-biotin) method. Sections of formalinfixed paraffin-embedded BM biopsies were prepared, followed by antigen retrieval in citrate buffer (pH 6, 30 minutes, 99°C). Sections were incubated with a rabbit anti-human IL2 antibody (1:125, Abcam, Cambridge, UK) overnight at 4 °C. Visualization was performed using Dako REAL Detection System/AP following the manufacturer's instructions. Samples were analyzed on a Nikon Eclipse 50i microscope with NISElements 4.13 acquisition software (Nikon, Düsseldorf, Germany). 
Bone marrow chimerism
Chimerism analyses were performed as previously described using a semiquantitative PCR approach based on the amplification of short tandem repeat (STR) markers (11) .
Briefly, genomic DNA for multiplex PCR of microsatellite markers was extracted directly from mononuclear cells. Nine tetra-nucleotide microsatellite regions were coamplified with dye-labeled primers using the AmpFLSTR Profiler PCR amplification kit (Applied Biosystems, Weiterstadt, Germany).
Results
Target expression in pre-therapeutic BM
TnC-A1 was expressed with a vascular and stromal pattern of staining in the BM of all three patients with BM AML involvement (Fig. 1A) , providing the molecular basis for an F16-based targeting approach. In patient 1 only paraffin-embedded chloroma material was available, which could not be analyzed for TnC-A1 expression, since the F16 antibody does not work in paraffin-embedded tissues (12) . However, we have previously observed that extramedullary AML lesions abundantly express TnC-A1 (5).
In vivo targeting of F16-IL2
Post-therapy BM biopsies were available in patients 2 and 4 to analyze the in vivo targeting capabilities of F16-IL2. Using an anti-IL2 antibody to detect F16-IL2 bound to its target in situ, IL2 signals decorating the extracellular matrix were detectable in the BM 6 days after the last infusion in patient 2, but not in pre-therapeutic BM (Fig. 1B) ,
suggesting that F16-IL2 has efficiently targeted TnC-A1 in vivo and persisted for several days. On day 42, however, three weeks after the last infusion of F16-IL2, stromal IL2 signals were not observed any more (Fig. 1B, inset) . In patient 4, no significant F16-IL2 signals could be observed 6 days after infusion.
Clinical courses
The Mio IU) and LDAC led to a blast reduction in PB (1080/µL) within one week (Fig. 3B) .
However, the patient had to be hospitalized after the first dose of F16-IL2 due to fevers (39.7 °C), chills, nausea and a reduced general condition. He was treated with broadspectrum antibacterials but it was again suspected that the fevers were more likely due to noninfectious hyperinflammation/cytokine-release. Indeed, signs of capillary leakage developed within the following days with generalized edema, weight gain (8 kg) and mild dyspnea. Laboratory findings showed elevated levels of IL6 (139 pg/mL, 10-fold increase from baseline), hyperferritinemia (11,600 µg/L) and a transient increase in creatinine (2.1 mg/dL). Fevers resolved by day 9 after four days of glucocorticoids. Creatinine normalized within four days, the patient`s weight returned to baseline by day 13, ferritin levels decreased to 3888 µg/L and he was discharged on day 15. F16-IL2 was not administered on days 8, 15 and 22. In a phase of rapid leukemia progression in PB the treatment was resumed on day 29 at 15 Mio IU F16-IL2 in an outpatient setting and was well tolerated at this time. Five days later, however, the patient had a severe accident at home and died due to intracerebral hemorrhage in the hospital shortly after. + cells on flow-cytometry, 12.3% at baseline) (Fig. 3C) . Microscopic quantification showed ≤ 5% myeloid leukemic blasts and an extensive infiltration with activated lymphocytes. In molecular and conventional cytogenetic analyses, the markers NPM1, t(2;3) and t(5;6) were undetectable, and BM donor cell chimerism increased to 96 
2214/µL after the 1 st cycle (Fig. 3C) , thereby meeting the criteria for a CR. However, after two cycles (two months after the first infusion of F16-IL2) the patient experienced a BM relapse with 15% blasts and reappearance of the molecular and cytogenetic abnormalities. The patient received two infusions of donor-derived lymphocytes without response and underwent a second matched unrelated alternative donor allo-HSCT in February 2014, but eventually died from infectious complications in the recovery time following transplantation.
Toxicities
All toxicities are summarized in Table 1 . The most frequent adverse events were fever, chills, and fatigue, which occurred in all patients. IL2-related infusion-associated hypotension was not observed. Tumor pain as observed in the chloroma patient is an uncommon effect of recombinant IL2 that could be related to F16-mediated targeting of the cytokine. In patients 2 and 4, fevers typically occurred either towards the end of the infusion or shortly after, regularly resolved by day 2 or 3 and were easily manageable at home with acetaminophen. In these patients, no other relevant non-hematologic toxicities occurred (apart from mild skin GVHD in patient 2).
However, the other two patients became significantly ill after the 1 st infusion of 
Immunological effects of F16-IL2
Circulating lymphocytes in PB significantly increased to levels 2 to 4 times as high as baseline levels by day 11 in all patients. Therapy-induced changes of peripheral lymphocyte subpopulations in patients 2 and 4 are shown in Fig. 4A 
from baseline. At peak levels, NK cells accounted for more than 50% of circulating lymphocytes. There were no significant changes in CD19 + B cells. Interestingly, activated lymphocytes and lymphocytes with large granular morphology could be readily detected in PB (Fig. 4B) .
The most prominent changes were observed in the BM. F16-IL2 led to a massive accumulation of lymphocytes in the BM (Fig. 4C and D) . 
Discussion
The increased angiogenic activity in AML BM has provided the scientific rationale for the clinical evaluation of anti-angiogenic agents in AML (8, (13) (14) (15) . However, therapeutic outcomes of angiogenesis inhibitors in AML have been mostly disappointing so far (16, 17) , stimulating the search for alternative strategies that take therapeutic advantage of angiogenic neovessels. Here, we report first-in-man experiences with the targeted delivery of IL2 to the leukemia-associated vasculature and stroma using the immunocytokine F16-IL2 in heavily pre-treated AML patients. We have chosen the situation after allo-HSCT to allow for a graft-versus-leukemia (GVL) response of a transplanted cellular immune system to the immunocytokine, and since we had previously treated two patients with late-stage refractory AML without previous allo-HSCT and had not observed significant anti-leukemic activity (data not shown). antibodies) (26) , might be even more efficient, yet at the expense of a potentially higher toxicity.
The fact that we observed aggravation rather than amelioration of GVHD symptoms contrasts with the notion of using IL2 to stimulate Tregs and suppress GVHD (19, 20) . Weekly IL2 equivalents that were administered in our patients were approximately 10 to 100-times higher than the doses used for GVHD. determine the net outcome of IL2-induced stimulation of pro-inflammatory and suppressive lymphocytes.
While F16-IL2 was well tolerated in two patients, the other two patients had substantial toxic side effects that either occurred immediately after the first infusion or cumulated after several infusions of F16-IL2. The cytokine-release syndrome that developed in both patients was manageable with high-dose glucocorticoids and did not reach the severity as reported for patients receiving chimeric antigen receptor-modified T cells (27) . Both patients tolerated re-exposure to lower doses of F16-IL2.
In principle, it is conceivable that the observed therapeutic effects could have also partially been achieved with the administration of free, unconjugated IL2. However, there are several lines of evidence, which strongly support the contribution of the targeting aspect to the therapeutic efficacy. First, the most pronounced changes in effector cell populations have been observed in the BM as compared to PB (e.g. up to 38-fold vs. 17-fold increase in NK cell numbers in BM vs. PB, respectively), which we would not expect from a non-targeted application of IL2. The fact that we still have seen considerable immunologic effects in the PB (and systemic toxicities) could be attributed to the "fluid" nature of the BM, which is -in contrast to solid tumors -part of the immune system and dynamically connected to the PB, allowing immune effector cells to traffic between BM and the periphery and to aggravate GVHD effects. Indeed, a comparable IL2-based immunocytokine only led to a modest increase in peripheral effector cell counts in patients, in which solid tumors have been targeted (28) . A dosefinding phase I study, which is currently in preparation, will tell whether lower starting doses of IL2 equivalents may lead to a more prominent discrimination between BM and PB immune effects. Second, the delivery of IL2 to the BM was demonstrated using immunohistochemical analyses of post-infusion BM biopsies. Stromal structures decorated with IL2 were detectable 6 days after the last administration of F16-IL2, indicating that the immunocytokine exhibited on-target persistence times of several days in vivo. In patients with solid tumors, comparable on-target persistence times have been 
extramedullary AML sites after each of the first two infusions of the immunocytokine, a side effect that is not commonly observed with non-targeted IL2. Tumor pain upon infusion has also been observed in patients with solid tumors receiving L19-IL2, an immunocytokine that targets EDB-Fn (28, 34) . Last, preclinical experiments using different syngeneic and xenograft models of AML have clearly shown that complete leukemia eradications could only be achieved with vascular-targeted IL2 in combination with cytarabine, while equimolar amounts of IL2 fused to an antibody of irrelevant specificity were ineffective in inhibiting leukemia progression (5).
In summary, a combination of F16-IL2 and LDAC can provide clinically meaningful benefit to patients in the desperate situation of AML relapse after allo-HSCT.
We believe that F16-IL2 combined with either LDAC or with additional immunologic maneuvers to increase on-target activity of the stimulated effector cells at the BM site, deserves further evaluation in prospective clinical trials, with a dedicated part on dosefinding, as it appears that patients with an allogeneic immune system may tolerate lower doses of F16-IL2 as compared to patients with solid tumors. 
